Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I read this as being mainly or even wholly optimistic too:
The revised agreement with DSM is a slightly pleasant surprise and put the control of the development of the existing market place firmly in our hands at a time when FF is starting to gain some ground in product awareness;
The development of FF in the "Gut Microbiome" market definitely caught me by surprise and the additional patent will add value to the underlying IP. It is interesting that DSM still wish to maintain control over this aspect of the product - but that can only be a good thing in terms of developing the market AND increasing the brand awareness.
The references to the progress in the development of the BH agreement shows no signs of a downside - indeed the update on the progress of the SAMR approval is positive and would appear to fit wholly within the timescale for the launch of the Agreement in Jan 2023;
A significant decrease in the financial loss for the last year. The possibility of reaching profitability of 23 or 24, and the chance that we will be spared a future fund raiser.
a huge derisk imho.
Plenty of cash in the bank atm.
Cash £1.077m at 31 March 2021
https://www.provexis.com/wp-content/uploads/2021/09/Provexis-plc-annual-report-31-Mar-21-FINAL-TYPESIGNED.pdf
The Company expects to release its preliminary results for the year ended 31 March 2022 in September 2022. The Company expects to report total revenue for the year of £426k and an underlying operating loss of £173k. The expected £173k underlying operating loss for the year is 23% ahead of the prior year (2021: an underlying operating loss of £225k) and is an all-time low number for the business.
https://otp.investis.com/clients/uk/provexis_plc/rns/regulatory-story.aspx?cid=1569&newsid=1597322
Tapping investors for more funds must take place in the next week or two or even sooner.
Yes, all very positive IMO and should see us making a profit sooner rather than later.
DSM, however, not willing to give up FF completely and obviously see something in the gut microbiome technology. Could be related to this study?
https://www.clinicaltrials.gov/ct2/show/NCT04160481
Will be interesting to read the patent and the publication when it comes out.
BB
looks like loose ends and tidy up ready for BH to make their move to me
W$
All sounds very positive and you'd hope will help turn us into a profitable business next year ?
Presumably we'll have to employ someone to manage the interface to our, new to us, customers.
I guess the only downside is that it means DSM no longer see spending money on developing FF as being good use of their capital, but our link up to DSM over the last 12 years hasn't really worked out as I'd hoped, so it's hard to see any great loss there.
BB
Top again.
http://www.by-health.com/news-4555
gixer,
Waiting for the day we see FF products mentioned in the best sellers :(
Really good presentation. Top marks to them.
wellsite,
I have a feeling that primary prevention might be a direction that China will aim towards but who knows.
hi gixer
Primary Prevention. Just noted this at DSM for 2019.
Solutions that don’t cause adverse side effects, however, can provide a new alternative in antiplatelet ingredients. Therefore Fruitflow® is a practical solution for a primary prevention-led approach.
https://www.dsm.com/human-nutrition/en/talking-nutrition/5-ways-fruitflow.html
W$
W$,
Looks very imressive. Thanks for sharing it. Hope their sales go exponentially, which in turn will increase FF sales
Tend to agree the attitude towards health claims can be dismissive, lots around,many hyped up beyond belief, but you got to be in it to win it, the smallest spark can cause a raging Inferno and maybe this will spark into life, many will be in profit with the share price rise over the last year but we know this is capable of going so much further if the SP can match the product health capabilities.
Don't you just love the way DP issues tasks to others?
Fully agree that Ian Ford is well aware of all current matters, updating of the website is necessary from time to time, although of limited value to shareholders, preaching to the choir. Given the breadth and scope of the health benefits of Fruitflow, I'm sure we all find it frustrating that sales volume isn't already greater, perhaps a reflection on the jaded attitude towards health claims in general.
DP
no need to contact IF, I'm sure someone at pixxie HQ has already read our latest ramblings.
Anyway, I believe BH & A N Other (DSM ,Bayer ?) are already carving out a deal between themselves to take us out......so not sure whether IF would bother at this late stage.
W-aimho-$
W$,
Very good point. May be you could approach IF with the idea and gixer's list. It is definitely a very good idea. They do not need to hire a programmer to do that. They could just contract out someone to do that bit of job. However they should use the wondefull research done by gixer for their own benefit.
wellsite,
I had noticed some slight changes to the site following your post.
gix
I like to think someone at PXS reads this board
My rant in April about how carp the website is seems to have been noted with the stuff below now removed and the narrative refreshed.
If I were running the show I would have a map showing where all the products are (made/sold/marketed, whatever is most useful) worldwide. With a bit of programming one can see evolution with time.
I would also have a map showing where FF+ is sold. Would be useful to see the impact of Brentford and Generations cup.
I don't think either would be commercially sensitive if a static map is updated say once a qtr and posted. A map of patent status could be done while they have a programmer on board.
IF needs to up his game re communication with shareholders. The excellent finds gixer is making need to be shared "officially" as to tbh statements like Primary Prevention need to be explained as they can impact share price..
W-feeling-confident-$
---------------------------------------------------------------------------------------------------------------------
BTW
I think IF should refresh our website reflecting all the progress (or just drop the section)
https://www.provexis.com/fruitflow/chinese-market/
https://www.provexis.com/fruitflow/asia-pacific-market/
Unless he reads this board then no he doesn't but I am sure he will have a good idea of what products have been launched. As for the website, I can't see that happening.
Hi gixer,
Many thanks for shring the list. Very impressive. Probably we are not too far to make profit. Does IF know that you have this comprehensive list? if not please let know so that he can put in their website.
Thanks alf, obviously not all products on the list are still available and some of the links are old and don't direct you to the correct page anymore but I would say the majority are still live products.
As you say though. Greater sales volume is coming.
It does work gix, it's an impressive list, ought to deliver enough revenues on it's own. The biggies are all ahead of us IMHO
DP64/everyone,
No idea if this will work but try this link for the list.
https://www.dropbox.com/scl/fi/9bkt8hwz74s6qkcbdd4nw/Products.docx?dl=0&rlkey=zhiudkmvyycucrf5kouh9hd8y
Some one is accumulating ,737 000 bought ,but not stating buy or sell